贝伐珠单抗与多柔比星脂质体联用对铂耐药复发性卵巢癌患者疾病控制率及远期预后的影响  

Effects of bevacizumab combined with doxorubicin liposome on disease control rate and long-term prognosis in patients with platinum-resistant recurrent ovarian cancer

作　　者：曹丽艳[1] 邵莎莎[1] 邱红楠 王光霞[1] 金海红[2] 龚姗[2] CAO Liyan;SHAO Shasha;QIU Hongnan;WANG Guangxia;JIN Haihong;GONG Shan(Department of Tumor Radiotherapy,Qinhuangdao First Hospital,Qinhuangdao 066000,Hebei,China;Department of Gynecology,Qinhuangdao First Hospital,Qinhuangdao 066000,Hebei,China)

机构地区：[1]秦皇岛市第一医院肿瘤放疗科,河北秦皇岛066000 [2]秦皇岛市第一医院妇科,河北秦皇岛066000

出　　处：《中国性科学》2025年第2期73-77,共5页Chinese Journal of Human Sexuality

基　　金：秦皇岛市科学技术研究与发展计划项目(20221606)。

摘　　要：目的探讨贝伐珠单抗与多柔比星脂质体联用对铂耐药复发性卵巢癌患者疾病控制率及远期预后的影响。方法选取2020年8月至2022年8月秦皇岛市第一医院收治的100例铂耐药复发性卵巢癌患者作为研究对象,按照随机数字表法分为观察组和对照组,每组50例。对照组采用贝伐珠单抗联合多西他赛化疗,观察组采用贝伐珠单抗联合多柔比星脂质体化疗。比较两组临床疗效、肿瘤标志物水平、不良反应发生情况、生存预后情况。结果观察组总有效率和疾病控制率高于对照组(P<0.05)。化疗前,两组糖类抗原125(CA125)、循环肿瘤细胞(CTC)、人附睾蛋白4(HE4)比较,差异无统计学意义(P>0.05);化疗后,两组CA125、CTC、HE4均低于化疗前,且观察组均低于对照组(P<0.05)。观察组胃肠道反应和白细胞减少发生率低于对照组(P<0.05)。观察组无进展生存期(PFS)和总生存时间(OS)长于对照组(P<0.05)。结论贝伐珠单抗联合多柔比星脂质体可有效降低铂耐药复发性卵巢癌患者肿瘤标志物水平,提高疾病控制率和总有效率,延长预后生存期,且不良反应在可控范围内。Objective To explore the effects of bevacizumab combined with doxorubicin liposome on disease control rate and long-term prognosis in patients with platinum-resistant recurrent ovarian cancer.Methods A total of 100 patients with platinum-resistant recurrent ovarian cancer in Qinhuangdao First Hospital from August 2020 to August 2022 were selected as study objects and divided into control group and observation group according to random number table method,with 50 cases in each group.The control group were treated with bevacizumab+docetaxel chemotherapy,and the observation group were treated with bevacizumab+doxorubicin liposome chemotherapy.The clinical curative effect,tumor markers levels,adverse reactions condition and survival prognosis in the two groups were compared.Results The total effective rate and disease control rate in observation group were higher than those in control group(P<0.05).Before chemotherapy,there was no significant difference in carbohydrate antigen 125(CA125),circulating tumor cells(CTC),human epididymal protein 4(HE4)when comparing in two groups(P>0.05).After chemotherapy,CA125,CTC and HE4 were all lower than before chemotherapy in the two groups,and were lower in observation group than control group(P<0.05).The incidence of gastrointestinal reactions and leukopenia in observation group were lower than those in control group(P<0.05).Progression free survival(PFS)and overall survival(OS)in observation group were longer than those in control group(P<0.05).Conclusions Bevacizumab combined with doxorubicin liposome can effectively reduce levels of tumor markers,increase disease control rate and total effective rate,prolong prognosis survival in patients with platinum-resistant recurrent ovarian cancer,with controllable adverse reactions.

关 键 词：铂耐药复发性卵巢癌 贝伐珠单抗 多柔比星脂质体 疾病控制率 预后 

分 类 号：R711[医药卫生—妇产科学]